📊 FBRX Key Takeaways
Is Forte Biosciences, Inc. (FBRX) a Good Investment?
Forte Biosciences is a pre-commercial stage biopharmaceutical company with minimal revenue ($1.3M) and massive operating losses (-$46.1M), burning substantial cash despite maintaining a strong balance sheet with $93.4M in cash. The company's business model shows no clear path to profitability in the near term, with negative free cash flow of -$34.5M and operating margins of -3507%, indicating fundamental challenges in drug development and commercialization.
Forte Biosciences has a strong cash position and low near-term balance sheet stress, but its fundamentals remain dominated by heavy operating losses, deeply negative margins, and substantial cash burn relative to its very small revenue base. Revenue growth is not yet meaningful enough to demonstrate durable operating traction, so the company’s financial profile still depends more on preserving cash and achieving clinical or commercial progress than on proven business economics.
Why Buy Forte Biosciences, Inc. Stock? FBRX Key Strengths
- Strong liquidity position with $93.4M in cash reserves and 7.34x current ratio providing runway for operations
- Manageable debt load with debt-to-equity ratio of 0.26x and no immediate solvency concerns
- Revenue growth of 16.9% year-over-year demonstrates some commercial progress, albeit from an extremely small base
- Very strong liquidity, with $93.41M in cash and current and quick ratios of 7.34x
- Low balance sheet strain relative to equity, with debt-to-equity of 0.26x and liabilities well below assets
- Revenue grew 16.9% year over year, indicating some top-line improvement from a small base
FBRX Stock Risks: Forte Biosciences, Inc. Investment Risks
- Unsustainable cash burn rate of $34.4M in operating cash flow will deplete capital reserves within 2-3 years without achieving profitability or securing additional financing
- Operating losses of $46.1M against $1.3M in revenue indicate severe clinical-stage company economics with no clear evidence of successful product commercialization
- Negative interest coverage ratio of -61.0x and negative returns on equity (-53.0%) and assets (-45.9%) demonstrate the company cannot service debt or generate returns from its asset base
- Operating and net margins are extremely negative, showing the business is far from self-sustaining
- Free cash flow of -$34.53M implies a meaningful cash runway risk if burn is not reduced
- Revenue remains too small relative to the cost structure to validate growth quality or profitability improvement
Key Metrics to Watch
- Cash burn rate and remaining runway - monitor quarterly operating cash flow to assess sustainability
- Revenue growth trajectory and product commercialization progress - critical to determine if revenue can scale meaningfully
- Clinical trial results and regulatory progress - essential for validating pipeline and potential future revenue opportunities
- Operating expense management - evaluate ability to achieve profitability or reduce burn rate
- Quarterly operating cash burn relative to cash balance
- Revenue scale-up and operating loss reduction over the next several reporting periods
Forte Biosciences, Inc. (FBRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.34x current ratio provides a solid financial cushion.
FBRX Profit Margin, ROE & Profitability Analysis
FBRX vs Healthcare Sector: How Forte Biosciences, Inc. Compares
How Forte Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Forte Biosciences, Inc. Stock Overvalued? FBRX Valuation Analysis 2026
Based on fundamental analysis, Forte Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Forte Biosciences, Inc. Balance Sheet: FBRX Debt, Cash & Liquidity
FBRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Forte Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-12.17 indicates the company is currently unprofitable.
FBRX Revenue Growth, EPS Growth & YoY Performance
FBRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2020 | $9.0K | -$10.3M | N/A |
| Q3 2019 | $9.0K | -$352.0K | N/A |
| Q2 2019 | $9.0K | -$16.0M | N/A |
| Q1 2019 | $9.0K | -$12.9M | N/A |
| Q3 2018 | $10.0K | -$352.0K | N/A |
| Q2 2018 | $9.0K | -$9.1M | N/A |
| Q1 2018 | N/A | -$9.1M | N/A |
| Q3 2017 | N/A | -$9.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Forte Biosciences, Inc. Dividends, Buybacks & Capital Allocation
FBRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Forte Biosciences, Inc. (CIK: 0001419041)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FBRX
What is the AI rating for FBRX?
Forte Biosciences, Inc. (FBRX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FBRX's key strengths?
Claude: Strong liquidity position with $93.4M in cash reserves and 7.34x current ratio providing runway for operations. Manageable debt load with debt-to-equity ratio of 0.26x and no immediate solvency concerns. ChatGPT: Very strong liquidity, with $93.41M in cash and current and quick ratios of 7.34x. Low balance sheet strain relative to equity, with debt-to-equity of 0.26x and liabilities well below assets.
What are the risks of investing in FBRX?
Claude: Unsustainable cash burn rate of $34.4M in operating cash flow will deplete capital reserves within 2-3 years without achieving profitability or securing additional financing. Operating losses of $46.1M against $1.3M in revenue indicate severe clinical-stage company economics with no clear evidence of successful product commercialization. ChatGPT: Operating and net margins are extremely negative, showing the business is far from self-sustaining. Free cash flow of -$34.53M implies a meaningful cash runway risk if burn is not reduced.
What is FBRX's revenue and growth?
Forte Biosciences, Inc. reported revenue of $1.3M.
Does FBRX pay dividends?
Forte Biosciences, Inc. does not currently pay dividends.
Where can I find FBRX SEC filings?
Official SEC filings for Forte Biosciences, Inc. (CIK: 0001419041) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FBRX's EPS?
Forte Biosciences, Inc. has a diluted EPS of $-3.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FBRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Forte Biosciences, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FBRX stock overvalued or undervalued?
Valuation metrics for FBRX: ROE of -53.0% (sector avg: 15%), net margin of -3,393.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FBRX stock in 2026?
Our dual AI analysis gives Forte Biosciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FBRX's free cash flow?
Forte Biosciences, Inc.'s operating cash flow is $-34.4M, with capital expenditures of $116.0K. FCF margin is -2,628.0%.
How does FBRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,393.2% (avg: 12%), ROE -53.0% (avg: 15%), current ratio 7.34 (avg: 2).